Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInspiration Hlt Regulatory News (IHC)

Share Price Information for Inspiration Hlt (IHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 16.00
Bid: 15.50
Ask: 16.50
Change: 0.00 (0.00%)
Spread: 1.00 (6.452%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 16.00
IHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

29 Sep 2011 07:00

RNS Number : 1460P
Inditherm PLC
29 September 2011
 



 

 

 

Press Release

29 September 2011

 

 

Inditherm plc

("Inditherm" or "the Company")

 

Interim Results

 

Inditherm plc, the provider of innovative heating solutions, is pleased to announce its Interim Results for the six months ended 30 June 2011.

 

Highlights

·;

Revenue increased by 10% to £817k (2010: £740k)

·;

Reduction in pre-tax loss for continuing operations of over 40% to £74k (2010: loss £124k)

·;

Reduction in overheads for continuing operations to £593k (2010: £601k)

·;

Encouraging growth in orders in quarters two and three after a disappointing first quarter

·;

Net cash and cash equivalents balance at 30 June 2011 of £1.5 million

·;

Recommendations from NICE (National Institute for Health and Clinical Excellence) supporting the use of Inditherm patient warming mattresses

 

Commenting on the outlook, Mark Abrahams, Chairman of Inditherm, said:

"After a slow start to the year, order intake in quarters two and three increased strongly compared with the same periods in 2010. This is encouraging and supports our belief that we can continue our growth.

 

"We believe that the recent NICE guidance in relation to our patient warming mattresses should stimulate faster growth in the UK medical market, linked with NHS budget cycles. Export orders continue to grow, as we benefit from our wider Medical distributor base and increasing market penetration.

 

"Divestment of the resource-intensive industrial activities has allowed us to reduce overheads and we believe that our focus on the medical segment is the best route to achieve profitability.

 

"Whilst we are expecting continued tough trading conditions, we are confident in our core medical business and the Board is continually evaluating ways of improving the business and maximising shareholder value."

 

- Ends -

 

For further information:

 

Inditherm plc

Nick Bettles, Chief Executive

nbettles@indithermplc.com

Tel: +44 (0) 1709 761000

Ian Smith, Finance Director

ismith@indithermplc.com

www.inditherm.com

 

Media enquiries:

Abchurch

Sarah Hollins / Oliver Hibberd

mailto:oliver.hibberd@abchurch-group.com

Tel: +44 (0) 20 7398 7714

 

 

 

Collins Stewart Europe (Nomad)

Matt Goode / Ileana Antypas

 

Tel: +44 (0) 20 7523 8350

 

 

 

Chairman's Statement

 

Introduction

 

The first half of 2011 has seen a continued improvement in revenue from continuing operations over the same period last year. Costs have been contained and the loss on continuing operations for the period has been significantly reduced compared with the same period last year. The elimination of losses associated with the Industrial Process Solutions business, following its disposal last year, has also contributed to the overall improvement.

 

Financial Review

 

Revenue from continuing operations increased by 10% to £817k (2010: £740k). At the end of August 2011 orders showed an underlying growth rate for the year of 17% for medical products and 38% from the non-medical sectors of the business. The performance of our Medical business in the UK has been impacted by delays in decision making resulting from financial uncertainty in the National Health Service (NHS). We believe this situation will be offset by the recent guidance from the National Institute for Health and Clinical Excellence (NICE) which we announced on 31 August 2011.

 

Overheads for continuing operations were reduced to £593k (2010: £601k) assisted by the directors' concessions on remuneration reported in the 2010 Annual Report, which are still in place. This combined with the improvement in trading delivered a reduction in pre-tax loss for continuing operations of over 40% to £74k (2010: loss £124k), resulting in a loss per share of 0.1 pence (2010: loss 0.2 pence).

 

The cash consumption from operating and investing activities was £183k (2010: £74k), giving a net cash and cash equivalents balance of £1,518k in hand at the half year. The uneven trading pattern in the first half led to an increased level of working capital at the end of June 2011. This level has subsequently reduced, releasing cash after the half year.

Operational Review

 

Order intake for the Medical business in the first quarter of 2011 was disappointing and significantly down on prior year levels, but there was a noticeable improvement during the second quarter, which was 60% up on the same period last year and consequently we finished the first half with modest growth. We have continued to see order growth into the second half in excess of 30%.

 

There remains uncertainty and associated delays in decision-making in the NHS; however, the new NICE guidance shows strong support for Inditherm's operating theatre products in terms of both clinical efficacy and significant financial benefits. We anticipate that as the NICE guidance starts to take effect it will progressively stimulate uptake as it gets embraced into the NHS budgeting process. The Company has worked for a long time to achieve recognition from NICE; it is an important milestone and whilst it does not guarantee success it is highly encouraging for the future. Despite the adverse market conditions, we have continued to show sales growth in the neonatal sector, largely due to our strong market position in the UK and growth in export territories. Our full range of warming products have been accepted into the new NHS Supply Chain contract.

 

Progress in the US medical sector has remained slow but has shown a modest improvement; this market offers potential up-side in the coming years, when we hope to be able to devote more resources to it. We have shifted our emphasis to our more focussed distributor, NovaMed, who are actively stimulating interest in the operating room market particularly, and Smiths Medical will no longer represent us in the USA. The Company believes that it remains important that the US market does not divert resources from our more immediate efforts to grow other export markets and we have further expanded our distributor network during 2011, particularly in South America.

 

Following the restructuring of the Industrial business in 2010, we now concentrate on the standard product offerings and good progress has been made year-on-year. We exited direct activity in the Process Solutions business area at the end of last year and first orders have now been received from our partners in this area, ADI Group. With the changed focus we now have an Industrial segment that is making a positive contribution.

 

Divestment of the resource-intensive industrial activities has allowed us to reduce overheads and we believe that our focus on the medical segment is the best route to achieve profitability.

 

Outlook

 

After a slow first quarter, we have seen an encouraging increase in order intake in quarters two and three compared with the same periods in 2010, albeit with an uneven order flow. Consequently we believe that we can continue our growth. This renewed optimism is predicated on the recent NICE guidance in relation to our products which should stimulate faster growth in the UK medical market, linked to NHS budget cycles. However we do recognise that the financial pressures currently facing the NHS give rise to more uncertain and erratic order patterns. Export orders continue to grow, as we benefit from our wider Medical distributor base and increasing market penetration.

 

Overall, despite the various factors impacting on our markets we continue to see an underlying growth in our Medical business.

 

The Company continues to direct its resources and focus on accelerating the growth of the Medical segment. The Board believe that this still gives the Company its best route to break-even.

 

 

Mark Abrahams, Chairman

29 September 2011

 

 

 

 

 

Unaudited consolidated statement of comprehensive income

For the six months ended 30 June 2011

 

Audited

 6 months

6 months

Year

ended

ended

ended

30-Jun

30-Jun

31-Dec

2011

2010

2010

Notes

£'000

£'000

 £'000

Revenue

817

740

1,324

Cost of sales

(303)

(267)

(519)

Gross profit

514

473

805

Administrative expenses

(593)

(601)

(1,222)

Operating loss

(79)

(128)

(417)

Finance income

5

4

8

Loss on ordinary activities before taxation

(74)

(124)

(409)

Taxation credit from loss on ordinary activities

3

-

1

27

Loss for the period on continuing activities

(74)

(123)

(382)

Loss for the period on discontinued activities

4

-

(53)

(106)

Loss and total comprehensive income for the period attributable to equity shareholders

(74)

(176)

(488)

Loss per share from continuing operations attributable to equity holders of the Company during the period - basic and diluted

(0.1p)

(0.2p)

(0.7p)

Loss per share from total Inditherm Group attributable to equity holders of the Company during the period - basic and diluted

5

(0.1p)

(0.3p)

(1.0p)

 

All recognised gains and losses are included in the income statement as such there is no other comprehensive income.

 

There is no difference between the results stated above and those prepared on the basis of historic cost equivalents.

Unaudited consolidated balance sheet

As at 30 June 2011

 

 

6 months

6 months

Audited

ended

ended

Year ended

30 June

30 June

31 December

2011

2010

2010

£'000

£'000

 £'000

Assets

Non-current assets

Property, plant and equipment

35

39

45

Intangible assets

67

84

75

102

123

120

Current assets

Inventories

183

100

132

Trade and other receivables

359

286

238

Tax receivable

25

39

32

Cash and cash equivalents

1,518

2,018

1,701

2,085

2,443

2,103

Liabilities

Current liabilities

Trade and other payables

(276)

(269)

(238)

Net current assets

1,809

2,174

1,865

Net assets

1,911

2,297

1,985

Shareholders' equity

Called up share capital

511

511

511

Share premium account

9,929

9,929

9,929

Share based payment reserve

134

134

134

Retained earnings

(8,663)

(8,277)

(8,589)

Total equity

1,911

2,297

1,985

 

Unaudited consolidated cash flow statement

For the six months ended 30 June 2011

 

Audited

6 months

6 months

Year

ended

ended

Ended

30 June

30 June

31 December

2011

2010

2010

Group

£'000

£'000

 £'000

Net operating loss for the period from continuing operations

(79)

(128)

(417)

Depreciation and amortisation

32

22

46

Increase in inventories

(51)

(3)

(35)

(Increase)/decrease in trade and other receivables

(121)

-

18

Increase/(decrease) in trade and other payables

38

(1)

(7)

Decrease in provisions

-

(5)

(5)

Interest received

5

4

8

Taxation received

7

41

74

Net cash outflow from operating activities

- continuing operations

(169)

(70)

(318)

- discontinued operations

-

-

(49)

Cash flow from Investing activities - continuing operations

Purchase of property, plant and equipment

(5)

(4)

(21)

Capitalised development costs

(9)

-

(3)

Sale of property, plant and equipment

-

-

-

Net cash used in investing activities continuing operations

(14)

(4)

(24)

Net decrease in cash and cash equivalents

(183)

(74)

(391)

Cash and cash equivalents at the beginning of the period

1,701

2092

2,092

Cash and cash equivalents at the end of the period

1,518

2,018

1,701

 

 

Unaudited consolidated statement of changes in shareholder equity

For the six months ended 30 June 2011

 

  

Audited

6 months

6 months

Year

ended

ended

ended

30 June

30 June

31 December

2011

2010

2010

£'000

£'000

£'000

Opening shareholders' equity

1,985

2,473

2,473

Loss for the period

(74)

(176)

(488)

Closing shareholders' equity

 

1,911

 

2,297

 

1,985

 

Notes to the interim report

 

1. Basis of preparationThis condensed consolidated interim financial information for the six months ended30 June 2011 has been prepared in accordance with AIM rule 18 in relation to half year reports. The information should be read in conjunction with the annual financial statements for the year ended 31 December 2010, which have been prepared in accordance with under International Financial Reporting Standards (IFRS) as adopted by the European Union.2. Going-concern basisThe group meets its day-to-day working capital requirements through its cash resources.The current economic conditions continue to create uncertainty particularly over thelevel of demand for the group's products. The group's forecasts and projections, taking account of reasonably possible changes in trading performance, show that the group should be able to operate within the level of its current resources. After making enquiries, the directors have a reasonable expectation that the group has adequate resources to continue in operational existence for the foreseeable future. The group therefore continues to adopt the going concern basis in preparing its consolidated interim financial statements.

 

3. Taxation

No corporation tax has been provided for in the period due to the projected result for the period not exceeding the losses brought forward.

Deferred tax assets arising from accelerated capital allowances and trading losses have not been recognised on the basis that their future economic benefit is uncertain.

 

4. Continuing/ Discontinued operations

 

Continuing activities in these accounts is in accordance with the provisions of IFRS 5 Non-current assets held for sale and discontinued operations.

 

On 13 December 2010, Inditherm plc transferred the Process Solutions business to the ADI group (ADI). Under this exclusive distribution agreement, Inditherm continues to make heating pads with ADI taking responsibility for all sales, marketing, design, installation and project management. Inditherm retained all activity related to their other Industrial products, including Intermediate Bulk Container (IBC), drum and cylinder heating systems.

 

The following analyses the result of the discontinued operations:

  

Continuing

Discontinued

Total

Total

Operations

Operations

Audited

Audited

Audited

6 months

Year

6 months

Year

6 months

Year

ended

ended

ended

ended

ended

ended

30-Jun

31 Dec

30-Jun

31-Dec

30-Jun

31-Dec

2010

2010

2010

2010

2010

2010

£'000

 £'000

£'000

 £'000

£'000

 £'000

Revenue

740

1,324

232

324

972

1,648

Cost of sales

(267)

(519)

(155)

(227)

(422)

(746)

Gross profit

473

805

77

97

550

902

Administrative expenses

(601)

(1,222)

(130)

(203)

(731)

(1,425)

Operating loss

(128)

(417)

(53)

(106)

(181)

(523)

Finance income

4

8

-

-

4

8

Loss before taxation

(124)

(409)

(53)

(106)

(177)

(515)

Taxation credit from loss on ordinary activities

1

27

-

-

1

27

Total deficit for the year attributable to equity holders

(123)

(382)

(53)

(106)

(176)

(488)

Loss per share - basic and diluted

(0.2p)

(0.7p)

(0.1p)

(0.3p)

(0.3p)

(1.0p)

 

 

5. Profit/ (loss) per share

 

The calculation of loss per ordinary share is based on a loss of £74,000 (30 June 2010: loss £176,000, 31 December 2010: loss £488,000) and on a weighted average number of shares in issue of 51,112,581 for the period, (30 June 2010: 51,112,581, 31 December 2010: 51,112,581). The outstanding share options are currently anti- dilutive.

 

  

6. Interim financial information

 

The interim financial information for the period ended 30 June 2011 is unaudited and does not constitute statutory accounts within the meaning of Section 434 of the Companies Act 2006. The Interim accounts for the six months ended 30 June 2010 are also unaudited and were approved by the Board of Directors on 23 September 2010. The comparative figures for the financial year ended 31 December 2010 are extracted from the audited accounts for that period. The company's annual report and financial statements for the year ended 31 December 2010 which were prepared under International Financial Reporting Standards (IFRS) as adopted by the European Union, International Financial Reporting Interpretations Committee (IFRIC) interpretations and with those parts of the Companies Act 2006 applicable to companies reporting under IFRS. The standards used are those published by the International Accounting Standards Board (IASB) and endorsed by the EU at the time of preparing those statements. The annual report and financial statements have been delivered to the Registrar of Companies with an unqualified audit report.

 

Copies of the announcement will be sent to shareholders and are available to members of the general public from the Company Secretary, Inditherm plc, Inditherm House, Houndhill Park, Bolton Road, Wath upon Dearne, S63 7LG or via the Company website at www.indithermplc.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR PGUAABUPGGQR
Date   Source Headline
1st May 20247:00 amRNSTrading update
9th Apr 20247:00 amRNSGrant of Options under Sharesave Scheme
1st Feb 202411:33 amRNSGrant of Covenant Waiver
31st Jan 20247:00 amRNSTrading update
18th Jan 20247:00 amRNSMDSAP certification
15th Jan 20243:04 pmRNSDirector/PDMR Shareholding
4th Jan 20247:00 amRNSStrategic acquisition of Airon Corporation
7th Dec 20237:00 amRNSDirectorate Change
2nd Nov 20237:00 amRNSLaunch of SLE1500 Non-Invasive Ventilator
31st Oct 202310:18 amRNSHolding(s) in Company
17th Oct 20237:00 amRNSDirector/PDMR Shareholding
16th Oct 20237:00 amRNSDirector/PDMR Shareholding
16th Oct 20237:00 amRNSDirector/PDMR Shareholding
16th Oct 20237:00 amRNSDirector/PDMR Shareholding
16th Oct 20237:00 amRNSDirector/PDMR Shareholding
12th Oct 20237:00 amRNSShareSoc investor presentation
3rd Oct 20237:00 amRNSHalf-year Report
22nd Sep 20237:00 amRNSInvestor results presentation
31st Aug 20237:00 amRNSTrading update
12th Jul 202310:45 amRNSHolding(s) in Company
10th Jul 20237:00 amRNSChange of Registered Office
27th Jun 202312:20 pmRNSResult of AGM
27th Jun 20237:00 amRNSAGM Statement
22nd Jun 20237:00 amRNSAppointment of Non-Executive Director
13th Jun 20232:00 pmRNSInvestor presentation
12th Jun 20237:00 amRNSCFO appointment
9th Jun 20237:00 amRNSGrant of Options
5th Jun 20235:13 pmRNSHolding(s) in Company
5th Jun 20237:00 amRNSHolding(s) in Company
2nd Jun 20237:00 amRNSNotice of AGM and posting of Annual Report
1st Jun 20233:27 pmRNSAIM Rule 17 Schedule Two (g) Update
1st Jun 20238:55 amRNSHolding(s) in Company
24th May 20237:00 amRNSAppointment of Nominated Adviser and Broker
17th May 20237:00 amRNSMello investor conference
4th May 20237:00 amRNSInvestor Day
3rd May 20237:00 amRNSFinal Results
6th Apr 20235:53 pmRNSGrant of Options
3rd Apr 20235:53 pmRNSGrant of Options
31st Mar 20236:27 pmRNSExercise of Options & Issue of Equity
23rd Mar 20237:00 amRNSLaunch of range extension of neonatal ventilators
1st Mar 20237:00 amRNSChange of Website
17th Feb 20232:05 pmRNSTR1 Notification
16th Feb 20237:00 amRNSTrading Update
9th Dec 20222:27 pmRNSTR1 Notification
8th Dec 20221:10 pmRNSTR1 Notification
5th Dec 20227:00 amRNSBoard Changes
30th Nov 202210:28 amRNSDirector / PDMR Dealing
28th Nov 20222:05 pmRNSSecond Price Monitoring Extn
28th Nov 20222:00 pmRNSPrice Monitoring Extension
28th Nov 20229:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.